Clinical Trials

Neuroblastoma, Ganglioneuroblastoma

NCT07480941 2026-03-18

DUAL-CAR-NK-GB

36 enrolled

Glioblastoma, Glioma

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06186401 2026-03-16

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

20 enrolled

Glioblastoma

NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

CNSGastrointestinalSarcoma

60 enrolled

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02389309 2026-03-09

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

14 enrolled

Brain Neoplasms

NCT04510051 2026-03-05

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Brain Neoplasms

NCT03152318 2026-03-04

rQNestin

62 enrolled

Astrocytoma, Brain Neoplasms, Disease, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma

NCT02574728 2026-03-02

AflacST1502

46 enrolled

CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

750 enrolled

Neuroblastoma, Ganglioneuroblastoma

NCT05382338 2026-02-24

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Phase 3 Recruiting

225 enrolled

Medulloblastoma

NCT01356290 2026-02-23

MEMMAT

232 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Ependymoma, Medulloblastoma, Recurrence

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06528691 2026-02-17

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

52 enrolled

Phase 4 Active not recruiting

Glioma, Central Nervous System Neoplasms

NCT02875314 2026-02-12

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

250 enrolled

Medulloblastoma

NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

130 enrolled

Brain Neoplasms, Medulloblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

45 enrolled

Phase 1 Not yet recruiting

Neuroblastoma

NCT07390539 2026-02-05

B7-H3.CD28Z.CART in CNS Neoplasms

70 enrolled

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningeal Neoplasms, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT05421897 2026-01-29

RAPID

11 enrolled

Neoplasms, Neuroblastoma

NCT07087002 2026-01-27

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Brain Neoplasms, Medulloblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT00336024 2026-01-23

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Phase 3 Completed

91 enrolled 24 charts

Medulloblastoma

NCT01175356 2026-01-23

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Phase 1 Completed

99 enrolled 11 charts

Neuroblastoma, Ganglioneuroblastoma

NCT01953900 2026-01-23

VEGAS

Phase 1 Not yet recruiting

26 enrolled

CNSSarcoma

Chickenpox, Neuroblastoma, Osteosarcoma

NCT07358260 2026-01-22

B7-H3.CD28Z.CART in Solid Tumors

40 enrolled

Neuroblastoma

NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

37 enrolled

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT04049669 2026-01-08

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

130 enrolled

Phase 3 Active not recruiting

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma

NCT02176967 2025-12-22

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

621 enrolled

Neuroblastoma, Ganglioneuroblastoma

NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

660 enrolled

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

NCT04539366 2025-11-03

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase 1 Suspended

67 enrolled

CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT03396575 2025-10-29

BRAVO

Phase 1 Terminated

11 enrolled

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Influenza, Human, Xanthomatosis, Cerebrotendinous

NCT04897321 2025-10-24

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

CNSDermatologicGastrointestinalGenitourinarySarcoma

32 enrolled

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT02605421 2025-10-21

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

12 enrolled

Neuroblastoma

NCT03786783 2025-10-09

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

42 enrolled 12 charts

BreastCNSDermatologicGynecologicSarcomaThoracic

Ganglioneuroblastoma

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

3 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Phase 1 Not yet recruiting

20 enrolled

Brain Neoplasms, Meningeal Carcinomatosis

NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1 Completed

65 enrolled 38 charts

Neuroblastoma

NCT03721068 2025-09-09

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Phase 1/2 Active not recruiting

CNSSarcoma

Gaucher Disease, Neuroblastoma, Osteosarcoma

NCT01192555 2025-08-01

ATOMIC

11 enrolled

Neuroblastoma

NCT02650648 2025-07-30

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Phase 1 Completed

85 enrolled

Neuroblastoma

NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies